ReCode Therapeutics to Participate in Upcoming July Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Company leadership will participate in two upcoming investor conferences in July:

• William Blair Biotech Focus Conference (New York, NY)
  Format: Panel Presentation
  Date: Wednesday, July 13, 2022
  Time: 2:00 - 2:45 p.m. ET

• Cowen RNA Therapeutics Summit (Virtual)
  Format: Panel Presentation
  Date: Thursday, July 21, 2022
  Time: 12:55 - 1:40 p.m. ET

About ReCode Therapeutics

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and on LinkedIn.